Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Allovir Inc ALVR

AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.


NDAQ:ALVR - Post by User

<< Previous
Bullboard Posts
Next >>
Post by a5a22406on Nov 18, 2005 1:48pm
504 Views
Post# 9872128

Cramer discusses Alvarion - 11/17/ '05

Cramer discusses Alvarion - 11/17/ '05Cramer is bullish on Israeli wireless broadband connectivity company Alvarion (ALVR:Nasdaq) as a play on the expected growth in WiMax. WiMax, said Cramer, could be huge as it has a range of 30 miles as opposed to WiFi, which is measured in feet. Alvarion has made a profit in just two years of its 10-year history, though, said Cramer. But, at $7.67 -- where the stock closed Thursday -- the stock is cheap, he said. Cramer believes that Alvarion's stock has bottomed and that the catalyst for the stock to move higher should come early next year when industry standards for WiMax are expected to be decided upon. Asked about the possibility of Alvarion getting acquired, Cramer said he never speculates on takeovers when a company's earnings are declining. He is "playing it for the earnings, and they've got to come back."
<< Previous
Bullboard Posts
Next >>